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Abstract 
Background: The hepatocyte growth factor (HGF)/c-Met signal pathway is up-regulated in human mesothelioma 
and suppression of the HGF/c-Met signaling with a competitive inhibitor, NK4 homologous to HGF in the structure, 
produced anti-tumor effects to mesothelioma in a preclinical study. Mesothelioma is highly resistant to a number of 
chemotherapeutic agents but distant metastasis to extra-thoracic organs is relatively infrequent until the late stage.
Methods/design: We planned to conduct a clinical study of gene therapy with adenoviruses expressing the NK4 
gene (Ad-NK4) to control the local tumor growth. The study is designed to inject Ad-NK4 into the intrapleural cavity 
with a dose escalation manner from 1010 to 1012 virus particles per patient and to examine safety and possible clinical 
benefits. The clinical investigation is a first-in-human trial to use the NK4 gene and to block the HGF/c-Met pathway 
with gene medicine. We conducted in vivo animal experiments to examine the safety level as one of the preclini-
cal studies, and showed that Ad DNA administered in the pleural cavity was detected in many parenchymal organs. 
Biochemical and pathological analyses showed that liver damages were the major adverse effects with little toxicity to 
other organs. These studies firstly demonstrated biodistribution and transgene expression after an intrapleural injec-
tion of Ad vectors in an animal study, which contrasts with an intravenous injection showing relatively rapid clearance 
of Ad-NK4.
Discussion: The clinical study can also provide information regarding production of NK4 protein and antibody 
against NK4, and inhibition levels of the HGF/c-Met pathway by detecting dephosphorylation of c-Met in mesothe-
lioma cells. These data will be crucial to judge whether local production of NK4 molecules can be an anti-cancer 
strategy.
Trial registration: UMIN clinical trials registry, Japan. Register ID: UMIN15771
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Background
Malignant mesothelioma is developed from mesothe-
lium and is associated mostly with occupational and less 
frequently with non-occupational asbestos exposures 
(Carbone et  al. 2002; Robinson et  al. 2005; Porpodis 
et  al. 2013; Røe and Stella 2015). A majority of meso-
thelioma, about 75% of the cases, is of pleura origin fol-
lowed by peritoneum. Malignant pleural mesothelioma 
tends to invade into the vicinity and disturbs functions 
of vital organs, which results in respiratory and cardiac 
failure, and spinal cord compression. Distant metasta-
sis to extrathoracic organs is however infrequent until 
the late stage. The latent period of mesothelioma after 
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asbestos exposure is long, more than 30 years in average, 
and a medical procedure to prevent the tumor develop-
ment is currently unknown. Detection of mesothelioma 
at an early stage is difficult because it is often asympto-
matic and the signs and symptoms are not specific to 
mesothelioma. Moreover, differential diagnosis from 
other cancerous and non-cancerous diseases needs care-
ful pathological examinations including several kinds of 
immunohistochemical staining.
Many industrial countries have inhibited asbestos 
usage, but emerging countries do not have a strict legal 
regulation. The asbestos consumption in the emerging 
countries rather increases in line with their economic 
development and an epidemiological analysis predicts 
an growing number of the patients in the countries par-
ticularly in Asia (Lin et  al. 2007). Moreover, mesothe-
lioma is resistant to current therapeutics despite recent 
multimodal treatments (Carbone et  al. 2002; Robinson 
et al. 2005; Opitz 2014; Kotova et al. 2015). Extrapleural 
pneumonectomy is one of the standard surgical proce-
dures but it is applicable only to an early-staged case. The 
recurrence is common even after the radical operation. 
Mesothelioma is essentially resistant to radiotherapy, 
which is used primarily for a palliative purpose. Systemic 
chemotherapy is thereby the primary treatment in most 
of the cases, and a combination of cisplatin (CDDP) 
and pemetrexed (PEM) is the first-line chemotherapy 
regimen over 10  years. Nevertheless, a mean survival 
rate with the CDDP plus PEM combination is merely 
12.1  months (Vogelzang et  al. 2003). Different possible 
chemotherapy regimens have been tested but none of 
them produced better clinical outcomes than the current 
first-line chemotherapy.
Biochemical analyses demonstrated aberrant growth 
signaling with enhanced angiogenesis in mesothelioma, 
which suggests that blocking these signal pathways is 
a therapeutic strategy. Mesothelioma often up-regu-
lated expression of vascular endothelial growth factor 
(VEGF), epidermal growth factor (EGF) and the cor-
responding receptors (VEGFR, EGFR) (Strizzi et  al. 
2001; Lee et al. 2007). Furthermore, an expression level 
of hepatocyte growth factor (HGF) and the receptor, 
c-Met, is also augmented in a majority of mesothelioma 
specimens (Jagadeeswaran et  al. 2006; Lee et  al. 2015). 
Molecular targeting agents that inhibit EGF/EGFR or 
VEGF/VEGFR pathway such as erlotinib, gefinitib and 
bevacizumab however failed to produce clinical benefits 
(Govindan et al. 2005; Garland et al. 2007; Dowell et al. 
2012; Ceresoli et al. 2013), but an inhibitor to block the 
HGF/c-Met pathway has not yet been examined for the 
efficacy to mesothelioma. Previous studies showed that 
the HGF/c-Met pathway played a crucial role in tumor 
invasion and metastasis, and blocking the pathway 
suppressed tumor infiltration into neighboring tissues 
(Matsumoto and Nakamura 2003). HGF is secreted as 
a precursor form and the pre-proHGF is subsequently 
cleaved into α and β chains with elastase actions, which 
results in a heterodimeric structure of mature HGF pro-
tein. The α chain is responsible for the binding to the 
c-Met receptor and the NK4 is a kind of an internal frag-
ment of HGF, being identical to the α chain sequences 
with a deletion of 16 amino acids. The NK4 molecules 
bind to the receptor but do not activate the downstream 
signal, demonstrating that NK4 is a competitive antago-
nist to block biological activities of HGF. Further investi-
gations revealed that NK4 also suppressed angiogenesis 
irrelevant to the VEGF/VEGF pathway and had a poten-
tial anti-cancer action by modifying a malignant behav-
ior of tumor cells (Kuba et  al. 2000; Sakai et  al. 2009). 
A number of preclinical studies demonstrated that 
adenoviruses (Ad) expressing the NK4 gene (Ad-NK4) 
produced anti-tumor effects on many types of tumors 
including mesothelioma (Saimura et al. 2002; Murakami 
et  al. 2005; Suzuki et  al. 2010). Transduction of meso-
thelioma with Ad-NK4 inhibited HGF-mediated phos-
phorylation of c-Met and the cell migration. Injection of 
Ad-NK4 into subcutaneous mesothelioma retarded the 
subsequent tumor growth. Moreover, administration 
of Ad-NK4 did not produce any major adverse effects 
in  vivo (Kishi et  al. 2009), and a majority of mesothe-
lioma do not have any genetic mutations at the c-Met 
locus that produce gain-of-functions (Lee et  al. 2015). 
These preclinical studies and analyses prompted us to 
conduct a clinical trial at Chiba University Hospital, 
Chiba, Japan, for chemotherapy-failed mesothelioma 
patients to examine safety and efficacy of an intrapleural 
injection of Ad-NK4.
Previous gene therapy for malignant pleural mesothelioma
Several clinical trials of gene therapy for mesothelioma 
have been conducted with the herpes simplex-thymidine 
kinase (HSV-TK) gene, or interferon (IFN)-α or -β gene 
at University of Pennsylvania (Sterman et al. 1998, 2005, 
2007, 2010, 2011). Some clinical case studies with repli-
cation-competent Ad or Ad expressing the p53 gene also 
included mesothelioma patients but the detailed infor-
mation about the mesothelioma cases was unavailable 
(Liu et al. 2006; Cerullo et al. 2010). The phase I studies 
with intrapleural administration of the Ad vectors dem-
onstrated that a maximum tolerance dose in the HSV-TK 
study was up to 5  ×  1013 virus particles (vp) (Sterman 
et al. 2005) and that in the IFN-β study was 1 × 1012 vp 
(Sterman et  al. 2007). The studies also showed that the 
Ad vectors induced gene transduction in mesothelioma 
and did not produce any major adverse effects (Ster-
man et al. 2005, 2007). These data collectively suggest a 
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feasible clinical study for malignant pleural mesotheli-
oma with an intrapleural injection of Ad-NK4.
Methods/design
Study drug
The agent, Ad-NK4, is type 5 Ad containing the expres-
sion cassette of the cytomegalovirus promoter-linked a 
full-length of NK4 cDNA followed by the SV40 T anti-
gen-derived poly A additional signal. The cGMP-grade 
vector was produced at GMJ Inc, Kobe, Japan, with 
PER.C6 cells which significantly inhibited generation of 
replication-competent Ad (RCA) (Fallaux et  al. 1998). 
Ad-NK4 for the clinical study were produced from the 
master virus bank and each vial contains 1.52 × 1012 vp/
ml. The Ad-NK4 products were confirmed to be free 
from various types of microorganisms and endotoxins. 
We also examined the frequency of RCA produced from 
the clinical grade vectors with A549 cells and the spike 
method (Ishii-Watabe et  al. 2003). The RCA frequency 
was less than 1 out of 3 ×  1010  vp at a sensitivity level 
that detected 1 RCA out of more than 3 ×  109 viruses. 
The vials were kept in a refrigerator at −80° and the viral 
titers remained unchanged for more than 5 years under 
the condition.
Study design and objectives
The study design is to administer 100  ml saline solu-
tion containing Ad-NK4 into the pleural cavity of mes-
othelioma patients who are not suitable for a surgical 
operation and fail to respond to the first-line chemo-
therapeutic agents (Figure 1). The study includes a dose 
escalation schedule with Ad-NK4 at 1 ×  1010, 1 ×  1011 
or 1 × 1012 vp per person and a single injection for each 
dose group consisting of 3 patients. The observation 
period of the study is 28 days but we follow-up them at 
an outpatient clinic. The primary endpoints are to inves-
tigate safety levels of Ad-NK4 injected into the pleural 
cavity and adverse effects produced, and to define the 
maximum tolerance dose. The secondary endpoints are 
evaluation of anti-tumor effects based on radiological 
imaging and of any improvements regarding patients’ 
quality of life and the performance status.
Subject selection and withdrawal
Inclusion criteria
Patients eligible for the study are those who are patho-
logically diagnosed as malignant pleural mesothelioma 
of locally advanced or recurrent cases, and not suitable 
for surgical resection. Those refuse to take the surgery 
irrespective of their clinical stages are also eligible. In 
addition, the patients who become refractory to chemo-
therapy or decline to receive chemotherapeutic agents are 
eligible. More than 4 weeks are required to be enrolled in 
the study after completing the precedent chemotherapy. 
Moreover, they should not have any treatment history of 
radiotherapy since radiation may produce delayed anti-
tumor effects. Patients, aged between 20 and 80  years 
old, must be fully explained about the study using a docu-
ment and give written informed consent.
Patients must have pleural effusion to have an enough 
space in the pleural cavity where Ad-NK4 is injected. 
The Eastern Co-operative Oncology Performance 
status must be 0 or 1. Female patients should not 
be pregnant or be lactating to nurse a baby. Patients 
must agree to use a physical method of contracep-
tion. Life expectancy of the patients will be longer 
than 3  months. Patients need to have adequate physi-
ological functions in major organs and the laboratory 
findings must be as follows: white blood cell, ≥3,000/
mm3 or neutrophil, ≥2,000/mm3; platelet, ≥1  ×  105/
mm3; hemoglobin, ≥9.0/dl; total bilirubin, less than 
1.5 times of a upper-limit of a normal range of the hos-
pital; aspartate transaminase (AST) and alanine ami-
notransferase (ALT), less than 2 times of a upper-limit 
of a normal range of the hospital; alkaline phosphatase, 
less than 5 times of a upper-limit of a normal range of 
the hospital; creatinine, <1.5 mg/dl, prothrombin time 
and activated partial thromboplastin time; within nor-
mal range; SPO2 (breathing in room air), ≥92%; electric 
cardiogram, within normal range.
Figure 1 A diagram of the study design. Enrollment of a patient needs more than 4 weeks after the last chemotherapy. Ad-NK4 is injected into the 
pleural cavity and then the patient will be monitored. The clinical study ends after day 29 but we will follow-up the patient thereafter.
Page 4 of 11Tada et al. SpringerPlus  (2015) 4:358 
The principle investigator and the medial collabora-
tors including those responsible for monitoring the cur-
rent study must approve that the patient is in an adequate 
condition to be enrolled in the study.
Exclusion criteria
Patients are not eligible for the study when they have 
active and uncontrollable infectious diseases, or any 
serious complications. Patients with a different type of 
malignancy, either synchronous or metachronous, are 
not eligible unless they are completely cured or their pro-
gression free interval is longer than 2 years. Patients who 
have symptomatic brain metastatic foci or those who 
require a treatment for the brain metastasis are excluded. 
Patients who do not have an enough intra-thoracic space 
for the viral injection or have participated in other clini-
cal trial(s) with approved or unapproved medicine within 
4 weeks before the entry of this study are not allowed to 
be enrolled. Those who are scheduled to receive another 
anti-cancer drug(s) during the study period or have 
received pleurodesis as a mesothelioma treatment are 
excluded. Patients who have peripheral nerve palsy at 
above grade 2 level (CTCAE ver 4.0) at the entry or have 
interstitial diseases and pulmonary fibrosis judged by 
chest X-ray are not eligible.
Those who have factors that prevent good compliance 
with the study protocol and the follow-up schedules, 
including some psychiatric, psychological, familial, social 
or geographical issues, are regarded as not being suit-
able for the study. Patients who have already undergone 
a treatment using Ad vectors or a treatment history of 
auto- or allograft organs transplantation, those who are 
positive for HIV antigen, HBV antigen, HCV antibody or 
HTLV-1 antibody, and those who are judged as inappro-
priate to participate in the study by the principal investi-
gator and the collaborators are excluded.
Safety tests in preclinical study
Many preclinical and clinical studies demonstrated 
safety and biodistributions of Ad that were adminis-
tered subcutaneously or intravenously (Reynolds et  al. 
1999; Hackett et  al. 2000). In contrast, biodistribu-
tion of Ad after an intrapleural injection has not yet 
investigated with an animal model although a clinical 
study for mesothelioma reported Ad in the sera after 
intrapleural administration (Sterman et  al. 2007). The 
clinical trial showed that sera of the patients became 
negative within a week when they received up to 
3 × 1012 vp in the thoracic cavity, but no further data 
in other tissues were included. We thereby conducted 
a preclinical study to examine biodistribution and pos-
sible adverse reactions with mice that received Ad-NK4 
in the pleural cavity.
Acute toxicity in intrapleural injection
We injected Ad-NK4 at 1.52 × 1011 vp/mouse (0.1 ml) or 
phosphate-buffered saline (PBS, 0.1 ml) as a control into 
the pleural cavity of CrlJ:CD1 mice (Japan Charles River, 
Yokohama, Japan). The maximum human dose used in 
the clinical study is 2 × 1010 vp/kg when an average body 
weight of patients is 50 kg, and a dose for the safety test 
with mice is 7.6 × 1012 vp/kg when that of mice is 20 g. 
The administered dose in mice thereby corresponded to 
380 times of the maximum human dose in the clinical 
study. We examined changes of body weights, biochemi-
cal tests, viral DNA distributions, transgene expres-
sions and pathological findings until day 14 as the acute 
toxicity.
Body weight We measured a body weight as a marker 
for general mouse condition (Figure 2a). The body weight 
of mice inoculated with Ad-NK4 temporally decreased 
on day 1 after the injection but the increase rate was not 
different from that of mice injected with PBS thereafter. 
Figure 2 Body weight changes in mice. a Ad-NK4 or PBS was administered in the pleural cavity of CrlJ:CD1 mice (n = 6). b Ad-NK4 were admin-
istered intravenously or into the pleural cavity of CrlJ:CD1 mice (n = 5). Average and SEs are shown. *P < 0.01 (analyzed with one-way analysis of 
variance).
Page 5 of 11Tada et al. SpringerPlus  (2015) 4:358 
Ad-NK4 administration may transiently suppress water or 
food intake in mice but produce little effects after day 2.
Hematological and biochemical data We conducted 
complete blood counting and biochemical analyses of 
the mice which received Ad-NK4 or PBS (Tables  1, 2). 
Numbers of white blood cells (WBC) and platelets were 
relatively higher in mice injected with Ad-NK4 than 
those with PBS (WBC day 14, P =  0.10; platelet day 1, 
P =  0.08) but the results of other laboratory tests were 
not markedly different between the groups (Table  1). 
The average blood glucose value was lower in Ad-NK4-
injected than in PBS-injected mice on day 1 (P  <  0.01), 
which could be associated with the temporal body weight 
loss on day 1. AST and ALT values in Ad-NK4-injected 
mice was greater than those in the control mice on days 
1 and 7 (P < 0.05) but the elevation became statistically 
insignificant thereafter (day 14: AST, P  =  0.055; ALT, 
P  =  0.089). Interestingly, the alkaline phosphatase val-
ues were lower in Ad-NK4-injected mice than in control 
mice on day 1 (P  <  0.05) but was not different thereaf-
ter. Moreover, the lactate dehydrogenase values were not 
statistically different between the groups through days 
1–14. These data suggested that intrapleural injection of 
Ad-NK4 produced liver damages rather than cholestatic 
injury, and the liver dysfunction came to be normalized 
thereafter. Differential data regarding the liver damages 
may be attributable to the fact that Ad vectors are prefer-
entially integrated into Kupffer cells rather than hepato-
cytes (Lieber et al. 1997). A few mice showed elevation of 
creatine phosphokinase values in both groups, the con-
trol group on days 7 and 14 and Ad-NK4-injected group 
on day 14, which could be due to some tissue damages at 
blood samplings.
Biodistribution of Ad-NK4 DNA We examined tis-
sue distributions of Ad-NK4 DNA with the real time 
polymerase chain reaction technique and calculated the 
copy numbers per 25 ng of genomic DNA extracted from 
respective tissues (Table 3). The DNA was detected in all 
the tissues tested, and the copy numbers in tissues were 
maximal on day 1 and decreased thereafter. Lung showed 
the largest amounts of DNA integration, and the copy 
numbers in liver were stable for 2 weeks after the injec-
tion in contrast to those in other tissues which decreased 
the numbers subsequently. These data suggested that 
Ad-NK4 administered in the pleural cavity infected lung 
through mesothelium and were transferred into systemic 
circulation. The copy numbers distributed in whole body 
became low thereafter but liver continuously harbored 
Ad-NK4.
Expression of NK4 mRNA We also examined transcript 
levels of NK4 in tissues of mice injected with Ad-NK4 in 
the pleural cavity (Table  4). The expression was signifi-
cant high in lung on day 1 and subsequently decreased. 
The rapid reduction was also observed in other tissues 
such as stomach. In contrast, the expression in liver was 
relatively stable.
Pathological findings Ad-NK4 injected into the pleu-
ral cavity induced mild degeneration of hepatocytes and 
infiltration of inflammatory cells in liver, but not necrosis 
on day 7 (Figure 3). The liver damages became less signif-
icant on day 14. Spleen showed mildly enlarged follicles 
in the lymph nodes but the findings became undetectable 
on day 14 (Figure 4). Other tissues including brain, lung, 
stomach, kidney, intestine, colon and testis did not show 
any pathological changes.
Long‑term effects in intrapleural injection
We examined long-term effects caused by Ad-NK4 with 
two different administration routes, intravenous and 
intrapleural injections. The body weight of mice received 
Table 1 Complete blood counting data of mice injected with Ad-NK4 or PBS
Data show average and SE values (n = 6). CrlJ:CD1 mice injected with Ad-NK4 were 5-week old male. Data of untreated CrlJ:CD1 male mice at 11-week old (Japan 
Charles river, Japan) as follows.
WBC, 20 ± 6.9 × 102 /μl; RBC, 943 ± 61 × 104/μl; Hgb, 14.8 ± 1.0 g/dl; Hct, 45.3 ± 2.4%; MCV, 48.1 ± 1.9 fl; MCH, 15.7 ± 0.5 pg; MCHC, 32.6 ± 0.5%; Plt, 
144.4 ± 18.9 × 104/μl.
Test Day 1 Day 7 Day 14
Ad-NK4 PBS Ad-NK4 PBS Ad-NK4 PBS
WBC (×102/μl) 17 ± 2 23 ± 4 36 ± 10 20 ± 2 83 ± 26 27 ± 7
RBC (×104/μl) 748 ± 20 674 ± 54 652 ± 32 736 ± 11 734 ± 32 713 ± 58
Hgb (g/dl) 13.3 ± 0.4 11.7 ± 0.7 11.2 ± 0.6 12.4 ± 0.1 12.6 ± 0.6 12.5 ± 0.7
Hct (%) 44.7 ± 1.2 40.2 ± 3.1 36.8 ± 2.0 40.8 ± 0.5 38.7 ± 1.8 37.8 ± 3.0
MCV (fl) 59.8 ± 0.4 59.7 ± 1.0 56.4 ± 1.1 55.4 ± 0.6 52.7 ± 0.1 53.0 ± 0.4
MCH (pg) 17.7 ± 0.2 17.4 ± 0.4 17.2 ± 0.4 16.9 ± 0.3 17.1 ± 0.1 17.7 ± 0.6
MCHC (%) 29.6 ± 0.2 29.1 ± 0.7 30.4 ± 0.4 30.4 ± 0.4 32.5 ± 0.1 33.3 ± 1.0
Plt (×104/μl) 109.9 ± 12.0 67.9 ± 18.8 55.4 ± 14.6 49.3 ± 10.6 83.9 ± 34.4 48.2 ± 23.8
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Ad-NK4 in the intrapleural cavity was less than that of 
mice injected intravenously on days 1 and 3 (P  <  0.01), 
but was not different thereafter (Figure  2b). Biochemi-
cal analyses on liver functions showed that AST and ALT 
values in the case of intravenous injections peaked on day 
7 and then decreased thereafter (Table  5). In contrast, 
changes of these data in the intrapleural injection were 
retarded and less significant in comparison with those in 
the intravenous injection (Tables 2, 5). Nevertheless, the 
transaminase values in the intrapleural injection were 
still above the normal range even on day 71. These data 
suggest that intrapleural injection of Ad vectors induced 
Table 2 Biochemical data of mice injected with Ad-NK4 or PBS
Data show average and SE values (n = 6). CrlJ:CD1 mice injected with Ad-NK4 were 5-week old male. Data of untreated CrlJ:CD1 male mice at 11-week old (Japan 
Charles river, Japan) as follows.
TP, 4.2 ± 0.3 g/dl; ALB, 2.3 ± 0.3 g/dl; BUN, 33.8 ± 8.6 mg/dl; CRE, 0.3 ± 0.09 mg/dl; Na, 153 ± 2 mEq/l; K, 4.6 ± 0.4 mEq/l; Cl, 106.7 ± 4.3 mEq/l; Ca, 8.8 ± 0.3 mg/
dl; IP, 7.9 ± 1.5 mg/dl; AST, 76 ± 11 IU/l; ALT, 32 ± 7 IU/l; ALP, 82 ± 31 IU/l; LDH, not available; CPK, 249 ± 96 IU/l; T-CHO, 151 ± 44 mg/dl; TG, 78 ± 58 mg/dl; T-BIL, 
0.08 ± 0.03 mg/dl; GLU, 101 ± 35 mg/dl.
Test Day 1 Day 7 Day 14
Ad-NK4 PBS Ad-NK4 PBS Ad-NK4 PBS
TP (g/dl) 5.4 ± 0.2 4.7 ± 0.1 4.6 ± 0.1 4.9 ± 0.1 5.0 ± 0.2 4.8 ± 0.1
ALB (g/dl) 2.8 ± 0.0 2.8 ± 0.1 2.6 ± 0.0 3.0 ± 0.0 2.8 ± 0.1 2.8 ± 0.0
BUN (mg/dl) 25.8 ± 1.0 23.6 ± 1.4 22.8 ± 0.9 24.5 ± 1.0 25.2 ± 0.9 28.0 ± 1.6
CRE (mg/dl) 0.14 ± 0.01 0.16 ± 0.01 0.13 ± 0.01 0.15 ± 0.02 0.14 ± 0.02 0.15 ± 0.01
Na (mEq/l) 153 ± 1 149 ± 1 151 ± 1 151 ± 1 149 ± 1 151 ± 1
K (mEq/l) 4.8 ± 0.2 4.4 ± 0.2 4.1 ± 0.2 3.9 ± 0.4 5.5 ± 0.5 4.3 ± 0.1
Cl (mEq/l) 101 ± 2 104 ± 0 106 ± 1 104 ± 1 105 ± 1 103 ± 2
Ca (mg/dl) 9.2 ± 0.1 9.6 ± 0.1 9.5 ± 0.1 9.5 ± 0.0 9.3 ± 0.1 9.5 ± 0.2
IP (mg/dl) 7.9 ± 0.4 9.7 ± 0.9 8.1 ± 0.1 7.8 ± 0.3 10.0 ± 0.9 7.1 ± 0.4
AST (IU/l) 191 ± 18 80 ± 18 383 ± 273 93 ± 32 347 ± 96 95 ± 13
ALT (IU/l) 131 ± 30 26 ± 7 312 ± 238 28 ± 3 244 ± 96 29 ± 3
ALP (IU/l) 198 ± 10 378 ± 43 407 ± 60 408 ± 79 448 ± 62 324 ± 30
LDH (IU/l) 3,352 ± 359 2,686 ± 826 2,535 ± 847 2,142 ± 287 2,622 ± 592 2,087 ± 271
CPK (IU/l) 1,262 ± 408 1,032 ± 412 432 ± 70 3,734 ± 3,283 4,493 ± 3,156 1,297 ± 387
T-CHO (mg/dl) 219 ± 11 147 ± 5 161 ± 8 169 ± 8 153 ± 8 176 ± 7
TG (mg/dl) 131 ± 17 109 ± 3 74 ± 13 40 ± 7 57 ± 6 119 ± 27
T-BIL (mg/dl) 0.05 ± 0.01 0.04 ± 0.00 0.09 ± 0.01 0.10 ± 0.01 0.08 ± 0.01 0.07 ± 0.01
GLU (mg/dl) 106 ± 7 169 ± 3 187 ± 12 173 ± 3 197 ± 8 192 ± 15
Table 3 Biodistribution of Ad-NK4 in mice injected into the pleural cavity
Data show average and SE values (n = 6). DNA from respective tissues was amplified to detect a Ad E4 region with the real time polymerase chain reactions as follows, 
a forward primer, 5′-CACCACCTCCCGGTACCATA-3′, a reverse primer, 5′-CCGCACCTGGTTTTGCTT-3′, and 40 cycles at 62°C for annealing. Ad reference material (VR-
1516, ATCC, Manassas, VA, USA) was used as a control.
Tissues Copy numbers of Ad-NK4 per 25 ng of total genomic DNA
Day 1 Day 7 Day 14
Brain 3.9 × 105 ± 1.7 × 105 3.4 × 103 ± 1.7 × 103 2.3 × 102 ± 1.0 × 102
Lung 3.1 × 108 ± 2.4 × 108 1.3 × 105 ± 3.9 × 104 7.5 × 103 ± 3.9 × 103
Stomach 1.5 × 106 ± 1.1 × 106 1.9 × 103 ± 4.3 × 102 3.4 × 102 ± 1.4 × 102
Spleen 6.4 × 105 ± 5.2 × 105 4.2 × 104 ± 1.6 × 104 2.6 × 103 ± 1.5 × 103
Kidney 1.3 × 104 ± 4.3 × 103 2.0 × 103 ± 6.3 × 102 2.1 × 103 ± 9.6 × 102
Liver 3.2 × 104 ± 1.9 × 104 1.9 × 104 ± 8.2 × 103 1.2 × 104 ± 1.1 × 104
Small intestine 1.1 × 104 ± 3.2 × 103 3.9 × 102 ± 2.0 × 102 6.5 × 102 ± 3.7 × 102
Colon 1.3 × 104 ± 7.1 × 103 9.8 × 102 ± 8.9 × 102 1.0 × 102 ± 35
Testis 4.5 × 103 ± 2.1 × 103 2.3 × 102 ± 94 45 ± 24
Blood 1.2 × 104 ± 4.6 × 103 2.4 × 103 ± 1.5 × 103 2.0 × 102 ± 92
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prolonged liver dysfunctions. We also compared tis-
sue distributions of Ad-NK4 with two different admin-
istration routes (Table  6). An intravenous injection of 
Ad-NK4 caused wide spread of Ad DNA in all the tis-
sues tested, and liver was the major organ that harbored 
the DNA on day 28. The copy numbers of Ad vectors in 
these tissues peaked on day 1 and decreased thereafter, 
but parenchymal organs showed constant Ad integra-
tions until day 28. Tissue distributions and the kinetics of 
Ad-NK4 DNA after the intrapleural injection were simi-
lar to and less than those after the intravenous admin-
istration. The copy numbers in the parenchymal organs 
remained similar from days 14 to 71 in the intrapleural 
injection. These data indicated that Ad vectors integrated 
in the parenchymal organs were not eliminated even 
10  weeks after the intrapleural injection, which may be 
linked with turnover levels of cells in these organs.
Discussion
There are several points to investigate in the current 
clinical research, which includes antibody produc-
tion, blocking of the HGF/c-Met signaling and clinical 
Table 4 Expression of  the NK4 gene in  mice injected 
with Ad-NK4 into the pleural cavity
Data show average and SE values (n = 6). First-strand cDNA was 
amplified with the real time polymerase chain reaction and with the 
NK4 primers, forward 5′-CGAGGCCATGGTGCTATACTC-3′, and reverse 
5′-TCAGCGCATGTTTTAATTGCA-3′, and the glyceraldehyde 3-phosphate 
dehydrogenase primers, forward 5′-AGCAAGGACACTGAGCAAGAG-3′, and 
reverse 5′-TATTATGGGGGTCTGGATG-3′, at 62°C for annealing and for 40 cycles. 
The NK4 mRNA amounts were estimated with the glyceraldehyde 3-phosphate 
dehydrogenase as a control and expressed as an arbitrary unit based on a 
standard sample.
Tissues Relative NK4 mRNA levels per 100 ng of synthe-
sized cDNA
Day 1 Day 7 Day 14
Brain 41.4 ± 8.0 2.4 ± 0.6 1.2 ± 0.3
Lung 21,563.1 ± 7,314.8 94.8 ± 37.9 10.5 ± 4.8
Stomach 244.9 ± 120.4 1.4 ± 0.4 6.2 ± 2.3
Spleen 111.6 ± 63.2 9.9 ± 2.9 3.6 ± 1.5
Kidney 13.7 ± 5.3 4.5 ± 2.4 1.2 ± 0.3
Liver 28.6 ± 2.8 25.3 ± 16.1 16.5 ± 5.4
Small intestine 34.6 ± 9.4 31.2 ± 2.0 9.3 ± 1.3
Colon 4.8 ± 1.5 1.7 ± 0.4 1.7 ± 0.4
Testis 2.8 ± 0.6 1.8 ± 0.2 0.5 ± 0.1
Figure 3 Representative liver sections of mice injected with Ad-NK4 on days 1, 7 and 14. The sections were stain with hematoxylin–eosin and the 
bars indicate 200 μm.
Figure 4 Representative spleen sections of mice injected with Ad-NK4 on days 1, 7 and 14. The sections were stain with hematoxylin–eosin and 
the bars indicate 200 μm.
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outcomes. Previous studies showed that almost all the 
patients developed neutralizing antibody against Ad 
structural proteins within 1  week after the intrapleural 
injection, and that the antibody production in an intra-
pleural administration seemed to have a similar kinetics 
as that in an intravenous injection (Molnar-Kimber et al. 
1998). Moreover, the antibody level in the pleural effu-
sion was the same as that in the serum (Molnar-Kimber 
et al. 1998). Peripheral T cells proliferated after a single 
Ad injection (Molnar-Kimber et  al. 1998), suggesting 
that T cells in general populations were already primed 
with Ad probably due to their previous respiratory infec-
tions. Likewise, humoral responses against Ad protein 
can be secondary immune responses. Interestingly, anti-
body was generated even against the transgene (Sterman 
et  al. 2007). These immune responses did not induce 
serious adverse reactions, and pre-existing humoral and 
cellular immunity prior to the Ad administration did 
not inhibit subsequent Ad-mediated gene transduction. 
Sterman et  al. (2010) examined whether multiple Ad 
Table 5 Comparison of AST and ALT values in different administration routes
Data show average and SE values (n = 5). CrlJ:CD1 mice injected with Ad-NK4 were 5-week old male. Data of untreated CrlJ:CD1 male mice at 11-week old (Japan 
Charles river, Japan) as follows.
AST, 76 ± 11 IU/l; ALT, 32 ± 7 IU/l.
Administration Enzyme activity (IU/L)
Day 1 Day 7 Day 14 Day 28 Day 42 Day 56 Day 71
AST
 Intravenous 801 ± 255 1,390 ± 492 644 ± 200 281 ± 81
 Intrapleural 214 ± 65 219 ± 38 202 ± 30 173 ± 23 169 ± 31
ALT
 Intravenous 356 ± 112 1,881 ± 648 1,031 ± 320 223 ± 62
 Intrapleural 361 ± 172 180 ± 63 205 ± 55 76 ± 12 65 ± 14
Table 6 Biodistribution of Ad-NK4 in different administration routes
Data show average and SE values (n = 5). Blood was negative for Ad-NK4 at any time irrespective of injection routes. The procedure to detect the copy numbers is the 
same as that in Table 3.
Tissues Copy numbers of Ad-NK4 per 25 ng of total genomic DNA
Route Day 1 Day 7 Day14 Day 28 Day 71
Brain
 Intravenous 6.5 × 105 ± 6.0 × 105 3100 ± 2200 520 ± 280 2500 ± 690
 Intraplueral 180 ± 80 370 ± 130 140 ± 50
Lung
 Intravenous 1.9 × 106 ± 8.9 × 105 3.3 × 105 ± 1.2 × 105 9.9 × 104 ± 4.0 × 104 1.3 × 105 ± 6.8 × 104
 Intrapleural 1.9 × 104 ± 4.1 × 103 7200 ± 2600 2.1 × 104 ± 7600
Spleen
 Intravenous 1.3 × 106 ± 1.3 × 106 6.2 × 104 ± 2.3 × 104 1.7 × 105 ± 3.9 × 104 2.0 × 105 ± 7.9 × 104
 Intrapleural 5.3 × 104 ± 2.2 × 104 7500 ± 2500 4.0 × 104 ± 1.3 × 104
Liver
 Intravenous 5.1 × 107 ± 4.0 × 107 9.5 × 105 ± 3.5 × 105 8.8 × 105 ± 1.6 × 105 8.7 × 105 ± 3.7 × 105
 Intrapleural 2.3 × 104 ± 1.6 × 104 1.4 × 104 ± 6900 5000 ± 1700
Kidney
 Intravenous 1.2 × 106 ± 2.6 × 105 2.0 × 104 ± 1.2 × 104 2.7 × 104 ± 1.6 × 104 2.8 × 104 ± 9200
 Intrapleural 2700 ± 660 1.0 × 103 ± 2000 1.7 × 103 ± 3600
Testis
 Intravenous 1.1 × 105 ± 4 .8 × 104 190 ± 170 70 ± 30 7,200 ± 7,000
 Intrapleural 120 ± 20 40 ± 20 440 ± 190
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administrations in a short period could increase gene 
transduction level and showed that the second injec-
tion 3  days after the first Ad administration increased 
the transgene expression probably because neutralizing 
anti-Ad antibody was not yet produced on day 3. We will 
therefore examine antibody titers against Ad hexon pro-
tein in patients’ serum and pleural effusion in the present 
study.
We also plan to conduct quantitative analyses of NK4 
molecules with an enzyme-linked immunosorbent assay 
system and further examine inhibition of the HGF/c-
Met signaling by Ad-derived NK4. A pleural effusion of 
the patient injected with Ad-NK4 is tested for the abil-
ity to dephosphorylate c-Met molecules in human mes-
othelioma cell lines or in patients-derived tumor cells if 
the samples are available. It is uncertain at this moment 
whether anti-NK4 antibody is produced by Ad-NK4 
administration since NK4 protein is naturally detected 
in human as a cleaved form of HGF. We speculate that 
NK4 molecules are less likely to be recognized as foreign 
substance by a host immune system and antibody against 
NK4 may not be produced. The minimal concentration of 
NK4 molecules to inhibit growth of mesothelioma in vivo 
is currently unknown. Clinical outcomes by Ad-NK4 
administration will be influenced by dependence lev-
els of mesothelioma on the HGF/c-Met pathway for the 
cell growth and on the angiogenesis which is produced 
by interactions between the tumors and the surround-
ing interstitial tissues. Previous studies showed that the 
transgene expression was detected only at superficial cell 
layers of the tumor tissues (Sterman et al. 2005) and we 
presume that changing body position after Ad injection 
can be beneficial to augment efficacy of the infections. 
Moreover, NK4 molecules are secretary protein and are 
consequently accumulated in the pleural space. Stability 
of NK4 molecules in vivo is however not well understood 
and sequential quantification of NK4 protein in the pleu-
ral effusion is important to estimate the NK4-mediated 
inhibition of HFG/c-Met pathways.
Previous clinical studies indicated that overall clinical 
responses were greater than the estimation based on the 
gene transduction efficacy (Sterman et  al. 2005, 2007). 
Moreover, tumor regression detected by tumor imaging 
techniques became evident even a few months after the 
Ad administration (Sterman et al. 2005, 2007), suggesting 
that the anti-tumor effects were attributable to possible 
systemic immune responses. In addition, post-treatment 
patients’ sera reacted with molecules that were expressed 
in several human mesothelioma cell lines, whereas pre-
treatment sera of the same patients did not. The molecu-
lar sizes that the antibody reacted were different among 
the respective cases, but the data suggested possible 
shared tumor antigens among human mesothelioma. 
Generation of antibody against unidentified molecules 
does not directly indicate activation of cell-mediated 
immunity against the putative antigen(s), but helper 
T cells, involved in either humoral or cellular immune 
responses, are activated by the same major histocompat-
ibility complex class II-binding peptide(s). Production 
of antibody against putative tumor antigen molecules 
thereby suggests induction of cytotoxic T cells targeting 
the molecules. Cell death caused by Ad vectors can facili-
tate uptake of putative tumor antigens by professional 
antigen presenting cells and Ad vectors can work as an 
adjuvant together with cytokines released from recruit-
ing inflammatory cells. These immune responses in the 
previous studies did not induce serious adverse reac-
tions, and pre-existing humoral and cellular immunity 
prior to the Ad administration did not inhibit subsequent 
Ad-mediated gene transduction (Molnar-Kimber et  al. 
1998; Sterman et  al. 2005, 2007). Migration of Ad vec-
tors from an intrapleural space into systemic circulation 
raises an issue of shedding from the patient body. We will 
monitor presence of the Ad vectors with the polymerase 
chain reaction in blood, urine and sputum of the tested 
individuals. The precedent study showed that sera of the 
patients were positive for Ad vectors for a week after an 
intrapleural injection (Sterman et al. 2007). It is however 
currently unknown how immune responses play a role in 
the decrease of Ad DNA from the systemic circulation.
Mesothelioma is histologically classified into three sub-
types, epithelioid, biphasic and sarcomatoid types. The 
sensitivity to chemotherapy is different among the sub-
types and prognosis of sarcomatoid type is in general the 
worst. A recent study also indicated a polyclonal origin 
of mesothelioma, which subsequently influences the che-
mosensitivity and the prognosis depending on a ratio of 
heterogeneity within tumors (Comertpay et  al. 2014). A 
clinical response to Ad-NK4 can also be varied among 
the histological subtypes as well. The present study how-
ever does not take the subtype into consideration at the 
patient enrollment since the study is a first-in-human 
trial regarding NK4 molecules and the primary endpoint 
is to investigate the safety of Ad-NK4. An examination of 
possible anti-tumor effects is the secondary endpoint but 
the patient number is too small to conclude the clinical 
outcomes.
The present protocol is to evaluate safety and then effi-
cacy of Ad-NK4 administered in the pleural cavity. Con-
firmation of safety of the gene therapy will promote next 
possible studies which include a combination of Ad-NK4 
and the first-line chemotherapy to a chemotherapy-naïve 
patient, and a phase II study with a maximum-tolerance 
dose of Ad-NK4.
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